肿瘤细胞治疗研究
FRONTIER PAPERS
Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.
我们的发现为在 CD1d 表达的血液系统恶性肿瘤患者中探索 CD1d-Vδ2 bsTCE 与 IMiD 来那度胺的联合治疗提供了依据。
Development and External Validation of a Transcriptome-Based Multivariable Prediction Model for Treatment-Free Remission in Chronic Myeloid Leukemia.
这些发现表明，在停用 TKI 时进行转录组分析可预测 CML 患者的 TFR 结局，并为持续 TFR 的潜在机制提供生物学见解。
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity.
Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of a
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.
Efficacy and Safety of Immune Checkpoint Inhibitors in the Treatment of Hematologic Malignancies: An Umbrella Review of Systematic Reviews and Meta-An
ICIs 在几种血液系统恶性肿瘤中显示出有前景的治疗潜力，尤其是 R/R NKT、MM、R/R CLL 和 R/R PMBCL。虽然安全性特征总体良好，但某些方案与可管理的毒性相关。未来研究应侧重于优化联合治疗、完善患者选择标准，并解决研究异质性，以增强 ICIs 在血液系统癌症中的临床应用。
Prognostic value of natural killer T cell related genes in acute myeloid leukemia.
本研究确定了 AML 的关键预后基因，并强调了 NKT 细胞在 AML 发病机制中的关键作用。该研究为理解 AML 生物学、预后和治疗靶点提供了新的见解和潜在生物标志物。
PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector Function.
Aggressive T-large granular lymphocytic leukemia with an aberrant natural killer T-cell phenotype in an adult and derivation of a novel cell line.
Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
